This article gives an overview of what is known and unknown about the epidemiology, diagnosis, risk factors, prevention and treatment for osteoporosis in men.
Get full access to this article
View all access options for this article.
References
1.
MeltonL.J.III, AtkinsonE.J., O’ConnorM.K., et al.Bone density and fracture risk in men. J Bone Miner Res, 1998; 13:1915–1923.
2.
O’NeillT.W., FelsenbergD., VarlowJ., et al.The prevalence of vertebral deformity in European men and women: The European Vertebral Osteoporosis Study. J Bone Miner Res, 1996; 11:1010–1018.
3.
LauE.M.C., LeeJ.K., SuriwongpaisalP., et al.The incidence of hip fracture in four Asian countries. The Asian Osteoporosis Study (AOS). Osteoporos Int, 2001; 12:239–243.
4.
LauE.M.C., DonnanS.P.B., BarkerD.J.P.Hip fracture in Hong Kong and Britain. Int J Epidemiol, 1990; 19:1119–1121.
5.
LauE.M.C., ChanY.H., ChanM., et al.Vertebral deformity in Chinese men: prevalence, risk factors, bone mineral density and body composition measurements. Calcif Tissue Int, 2000; 66:47–52.
6.
LauE., ChanH., WooJ., et al.Normal ranges for and the prevalence of vertebral fracture in Hong Kong Chinese. J Bone Miner Res, 1996; 11:1364.
KanisJ.A.An update on the diagnosis of osteoporosis. Curr Rheumatol Rep, 2000; 2:62–66.
9.
ChengS., SuominenH., Sakari-RantalaR., et al.Calcaneal bone mineral density predicts fracture occurrence: a five-year follow-up study in elderly people. J Bone Miner Res, 1997; 12:1075–1082.
10.
KanisJ.A., JohnellO., AdenA., et al.Ten-year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. J Bone Miner Res, 2001; 16:S194.
11.
OrwollE.Assessing bone density in men. J Bone Miner Res, 2000; 15:1867–1870.
12.
National Osteoporosis Foundation. Physicians guide to prevention and treatment of osteoporosis. 2003.
ClowesJA, EastellR. Markers of bone turnover and the laboratory evaluation of secondary osteoporosis. In: Osteoporosis: an evidence-based guide to prevention and management. Philadelphia: American College of Physicians; 2002.
15.
OrwollE., EttingerM., WeissS., et al.Alendronate for the treatment of osteoporosis in men. N Engl J Med, 2000; 343:604–610.
16.
RingeJ.D., FaberH., DorstA.Alendronate treatment of established primary osteoporosis in men; results of a 2-year prospective study. J Clin Endocrinol Metab, 2001; 86:5252–5255.
17.
SaagK.G., EmkeyR., SchnitzerT.J., et al.Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med, 1998; 339:292–299.
18.
WallachS., CohenS., ReidD.M., et al.Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int, 2000; 67:277–285.
19.
AdachiJ.D., SaagK.G., DelmasP.D., et al.Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum, 2001; 44:202–211.
20.
SmithM.R., McGovernF.J., ZietmanA.L., et al.Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med, 2001; 345:948–955.
21.
OrwollE.S., OviattS.K., McClungM.R., et al.The rate of bone mineral loss in normal men and the effects of calcium and cholecalciferol supplementation. Ann Intern Med, 1990; 112:29–34.
22.
HeikinheimoR.J., InkovaaraJ.A., HarjuE.J., et al.Annual injection of Vitamin D and fractures of aged bones. Calcif Tissue Int, 1992; 51:105–110.
23.
AndersonF.H., FrancisR.M., FaulknerK.Androgen supplementation in eugonadal men with osteoporosis-effects of 6 months of treatment on bone mineral density and cardiovascular risk factors. Bone, 1996; 18:171–177.
24.
AndersonF.J., FrancisR.M., PeastonR.T., et al.Androgen supplementation in eugonadal men with osteoporosis: effects of six-months’ treatment on markers of bone formation and resorption. J Bone Miner Res, 1997; 12:472–478.
25.
BehreH.M., KlieschS., LeifkeE., et al.Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. J Clin Endocrinol Metab, 1997; 82:2386–2390.
26.
HamdyR.C., MooreS.W., WhalenK.E., et al.Nandrolone decanoate for men with osteoporosis. Am J Ther, 1998; 5:89–95.
